# Real‐life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy‐cell leukemia: A multicenter Italian retrospective study (HCL‐PG03R)

**Authors:** Luca De Carolis, Monia Capponi, Andrea Bernardelli, Andrea Visentin, Gianna Maria D'Elia, Simone Ferrero, Michele Cimminiello, Azzurra Romeo, Barbara Pocali, Luciana Morino, Alessandro Sanna, Ombretta Annibali, Francesca Ricci, Flavio Falcinelli, Alessandro Mancini, Francesco Angotzi, Anna Maria Frustaci, Nilla Maschio, Caterina Stelitano, Alessandro Gozzetti, Riccardo Moia, Maura Nicolosi, Silvia Trappolini, Valerio Leotta, Alessandro Pulsoni, Robin Foà, Carlo Visco, Roberta Murru, Jacopo Olivieri, Livio Trentin, Brunangelo Falini, Enrico Tiacci

PMC · DOI: 10.1002/hem3.70255 · 2025-11-14

## Full-text entities

- **Diseases:** hairy-cell leukemia (MESH:D007943)
- **Chemicals:** rituximab (MESH:D000069283), vemurafenib (MESH:D000077484)

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12616395/full.md

---
Source: https://tomesphere.com/paper/PMC12616395